Axsome Therapeutics (AXSM) Common Equity (2015 - 2026)

Axsome Therapeutics has disclosed Common Equity across 12 years of filings, most recently posting $54.6 million for Q1 2026.

• Common Equity for Q1 2026 came in at $54.6 million, up 2.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $54.6 million (up 2.6% YoY), and the FY2025 annual result was $88.3 million, up 54.86% from the prior year.
• Common Equity came in at $54.6 million for Q1 2026 at Axsome Therapeutics, down from $88.3 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $278.8 million in Q2 2023 to a low of $14.7 million in Q1 2022.
• The 5-year median for Common Equity is $92.9 million (2024), against an average of $111.0 million.
• Across the five-year window, Common Equity sank 84.74% in 2022 and jumped 1734.36% in 2023, its largest moves.
• Axsome Therapeutics' Common Equity stood at $109.6 million in 2022, then soared by 74.32% to $191.0 million in 2023, then plunged by 70.15% to $57.0 million in 2024, then soared by 54.86% to $88.3 million in 2025, then tumbled by 38.18% to $54.6 million in 2026.
• The last three Common Equity figures came in at $54.6 million (Q1 2026), $88.3 million (Q4 2025), and $73.7 million (Q3 2025), per Business Quant data.